Background: Current therapeutic modalities for fibromyalgia syndrome (FMS) do not provide satisfactory results to a high percentage of patients and new approaches have to be explored. Objectives: This randomised, double-blind, controlled study was aimed to assess the efficacy and safety of adding a new treatment of herbal medicine, specifically developed to improve the quality of life of patients with FMS , to the current therapeutic regimen. Methods: In this double-blind, placebo-controlled study, females with FMS, insufficiently improved by their current treatments, were randomised in one of the 3 following arms: Patients of arm 1 received Fib-19-01, 1 tablet twice a day. Those of arm 2 received a food supplement claimed to have analgesic properties (FSAP), in a double-blind way, and patients of arm 3 continued the previous treatment. without adding anything else (NoT). All continued the conventional treatment throughout the 6 months of follow-up. Inclusion criteria: women suffering from FMS (ACR criteria) with a Fibromyalgia Index Questionnaire FIQ >46. The primary endpoint was the change in FIQ score between baseline (Day 0) and month 6 (M6). Secondary Criteria included variation between D0 and M6 of the following scores: Pichot scale, Pittsburgh Sleep Quality Index (PSQI) index, SF-12 mental and social, SF-12 physical, HAD scales for depression and anxiety. Statistical analysis: Comparison intra-group (D0-M6) and intergroup on the ITT population. Results: The ITT and per protocol populations were constituted of 101 and 75 patients. They were not statistically different and were in accordance with that expected (age 49, BMI 25, high percentage of antidepressant and anticonvulsant treatments). FIQ decrease throughout the follow-up was significant only in the Fib-19-01 group; (p<0.001). In intergroup comparison, improvement was higher for Fib-19-01 (-13.5) than in the 2 other groups (-5.4 and -5.6) but the difference did not reach statistical significance (p=0.08). Analysis of variance in repeated measurements of FIQ showed a significant difference between Fib-19-01 and FSAP (p=0.03). On the secondary criteria, only Fib-19-01 patients were improved for PICHOT scale (p<0.001), PQSI (p=0.02), SF12 mental and social (p<0.001), HAD anxiety (p=0.003) and depression (p=0.004). In intergroup comparison Fib-19-01 was superior to FSAP for Pichot scale (p=0.013), mental and social SF12 (p=0.018), HAD depression (p=0.013). No significant difference was found between FSAP and NoT groups. Therefore, in this study FSAP acts as a placebo which gives the results of this study a level of evidence I. All treatments were well and similarly tolerated. Conclusions: A 6-month treatment with Fib-19-01 improved all FMS scores excepted the physical SF 12, as opposed to FSAP and conventional treatment alone, which did not significantly improve any. This study showed that Fib-19-01 has a therapeutic effect in the FMS chiefly on the components "fatigue", "emotion and social life" and "depression" of the disease, without safety concern. (2) 1990 ACR Classification Criteria. Methods: Patients referred to a tertiary care centre with suspicion of Fibromyalgia were evaluated using the Proposed 2016 revision. Patients with other rheumatological diseases were excluded. Considering the expert physician opinion and American College of Rheumatology (ACR) 1990 Classification as gold standards, sensitivity, specificity, and likelihood ratios were calculated. Also, validated Hindi language versions of Brief Patient Health Questionnaire (BPHQ), Generalised Anxiety Disorder-7 (GAD7), and Toronto Alexithymia Scale-20 (TAS20) were filled up by the participants. Results: Out of 101 patients, 77 were diagnosed as Fibromyalgia by the expert. The 2016 criteria and ACR1990 criteria were met by 79 and 67 patients respectively. The 2016 had high sensitivity but much lower specificity as compared with either the expert diagnosis or ACR1990 criteria (Table 1) . Visual Analogue Scale (VAS) for pain, BHPQ, GAD7, and TAS20 scores were 7.2±2.3, 14.1±5.1, 11.3±5.5 and 58.0±14.0 (Mean±SD) respectively. Patients with or without fibromyalgia as per each of the three criteria had no significant difference in these scores. Background: Fibromyalgia (FM) can be a comorbid condition in axial spondyloarthritis (axSpA). FM screening questionnaires and classification criteria fulfillment may demonstrate different prevalence and patients' characteristics may differ. Objectives: To evaluate frequency of comorbid FM, and the differences between axSpA patients with/without comorbid FM according to screening (FiRST) and classification tools (ACR1990 FM criteria). Methods: A multicenter national study involving 39 rheumatology centers in France included 519 patients with axSpA starting an anti-TNF treatment (PredictSpA study; ClinicalTrials.gov: NCT03039088). Patients (pts) were screened for FM with the FiRST questionnaire and classified as FM by ACR 1990 criteria. Demographic characteristics, comorbidities, axSpA characteristics, CRP and imaging were recorded in all patients. Kappa coefficient (and its 95% CI) was calculated to compare FiRST and ACR1990 criteria. Baseline characteristics associated with FM were evaluated by univariable and multivariable logistic regression (including the variables with a p value<0.20 in the univariable analysis). Results: In the 519 pts (females: 46%, age: 42±12 years, mean BASDAI 5.7±2.0, mean ASDAS-CRP 3.3±0.9), a comorbid FM was screened in 38% and diagnosed in 16% of pts. Agreement between FiRST and ACR1990 was poor, with a Kappa
In the multivariable analysis, comorbid FM (by the FiRST questionnaire) in axSpA Background: Auto-antibodies to the RNA binding protein Ro60 are present in patients with autoimmune disorders such as systemic lupus erythematosus (SLE). In addition to its established role as an auto-antigen, Ro60 has been found to bind Alu RNA retroelements whereby it may target Alu retroelement RNA for degradation suggesting a novel putative function of this auto-antigen. If Ro60 modulates the amount of cellular RNA then one may hypothesise an association with toll-like receptor (TLR) 7 stimulation threshold. Objectives: To measure the physiological levels of intracellular Ro60 protein in healthy children and adolescents and investigate a possible link between Ro60 protein expression and interferon-α (IFN-α) production after TLR7 stimulation. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from blood from 48 healthy children and adolescents (age range 6.7-17.9 years old). Cell lysates from thawed PBMC samples were tested for Ro60 expression by Western blot. PBMCs were also stimulated for 20 hours with TLR7/8 agonist R848, at 1ug/ml in the presence of brefeldin A, and plasmacytoid dendritic cell (pDC) IFN-α expression was measured using flow cytometry. Statistical tests to measure correlation between IFN-α expression in (pDCs) and PBMC Ro60 expression were performed using SPSS. Results: Ro60 expression in PBMCs correlated negatively with age (Spearman's rho = -0.317, p=0.032). When participants were divided into two groups based on their self-reported puberty status, Ro60 expression was higher in the pre-pubertal group (p=0.02). There was, however, no difference in Ro60 expression between males and females (p=0.44) or when sexes were stratified according to pubertal status. pDC IFN-α production after TLR 7 stimulation, did not correlate with ex vivo PBMC Ro60 expression overall (Spearman's rho =0.159, p=0.302) however a moderate positive correlation was observed in pre-pubertal samples only (Spearman's rho =0.554, p=0.021). Conclusions: Ro60 expression decreases with age in healthy young people. These findings need to be confirmed in a larger cohort and further studies are necessary to investigate the link between Ro60 expression and TLR7 signalling across different age groups as well as in patients with SLE. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5073
